
# Methyl-β-cyclodextrin

MedChemExpress

| Cat. No.: | HY-101461   |              |                    |
|-----------|-------------|--------------|--------------------|
| CAS No.:  | 128446-36-6 | 5            |                    |
| Target:   | Biochemica  | l Assay Re   | eagents            |
| Pathway:  | Others      |              |                    |
| Storage:  | Powder      | -20°C<br>4°C | 3 years<br>2 years |

R



**Product** Data Sheet

## SOLVENT & SOLUBILITY

| In Vitro | DMSO : ≥ 100 mg/mL                           |  |
|----------|--|--|
|          | $H_2O: \ge 50 \text{ mg/mL}$                 |  |
|          | * "≥" means soluble, but saturation unknown. |  |

| BIOLOGICAL ACTIVITY |   |  |
|---------------------|---|--|
| Description         | Methyl-β-cyclodextrin (Methyl-beta-cyclodextrin) is a cyclic heptasaccharide used to deliver hydrophobic agents based on<br>its property of solubilizing non-polar substances. Methyl-β-cyclodextrin is also extensively used as a cholesterol-depleting<br>reagent <sup>[1]</sup> . Methyl-β-cyclodextrin strongly reduces clathrin-dependent endocytosis <sup>[2]</sup> . Methyl-β-cyclodextrin blocks cell<br>migrasome formation <sup>[3]</sup> .   |  |
| In Vitro            | Methyl-β-cyclodextrin is extensively used to increase the permeability of cells, and thereby increase the uptake of small molecules such as glucose and nano-particles <sup>[4]</sup> .<br>Cyclodextrins are a family of cyclic oligosaccharides with a hydrophilic outer surface and a lipophilic central cavity.<br>Cyclodextrins molecules are relatively large with a number of hydrogen donors and acceptors and, thus in general, they do not permeate lipophilic membranes. In the pharmaceutical industry, cyclodextrins have mainly been used as complexing agents to increase aqueous solubility of poorly soluble drugs and to increase their bioavailability and stability. Cyclodextrins are used in pharmaceutical applications for numerous purposes, including improving the bioavailability of drugs <sup>[4]</sup> .<br>Methyl-β-cyclodextrin quickly induces caspase-dependent apoptosis in PEL cells via cholesterol depletion from the plasma membrane. Methyl-β-cyclodextrin inhibits the growth of all PEL cell lines in a dose-dependent manner. The IC <sub>50</sub> is 3.33-4.23 mM in each cell line <sup>[5]</sup> .<br>Methyl-β-cyclodextrin is a highly water soluble cyclic heptasaccharide consisting of a β-glucopyranose unit, has been reported as the most effective agent for the depletion of cholesterol from cells among the various cholesterol-depleting agents <sup>[5]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |  |
| In Vivo             | In a PEL xenograft mouse model, Methyl-β-cyclodextrin significantly inhibits the growth and invasion of PEL cells without apparent adverse effects. Methyl-β-cyclodextrin-treated mice appears to be healthy, whereas non-treated mice has a distended abdominal region. The body weights of control are significantly higher than those of Methyl-β-cyclodextrin treated mice has a significantly lower volume of ascites than that of non-treated mice <sup>[4]</sup>   |  |

Studies in both humans and animals have shown that cyclodextrins can be used to improve drug delivery from almost any type of drug formulation. Currently, there are approximately 30 different pharmaceutical products worldwide containing drug/cyclodextrins complexes in the market<sup>[6]</sup>.

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

| PROTOCOL                                |  |
|---|--|
| PROTOCOL                                |  |
| Cell Assay <sup>[1]</sup>               | PEL cells are incubated in triplicate in a 96-well microculture plate in the presence of different concentrations of methyl-β-<br>cyclodextrin (0-10 mM) in a final volume of 0.1 mL for 24 h at 37°C. Subsequently, MTT (0.5 mg/mL final concentration) is<br>added to each well. After 3 h of additional incubation, 100 μL of a 0.04 N HCl is added to dissolve the crystals. Absorption<br>values at 570 nm are determined <sup>[1]</sup> .<br>MCE has not independently confirmed the accuracy of these methods. They are for reference only. |
| Animal<br>Administration <sup>[1]</sup> | Mice: Female NRJ mice are intraperitoneally inoculated with BCBL-1 cells suspended in PBS. The mice are then treated with intraperitoneal injections of PBS or methyl-β-cyclodextrin (500 mg/kg per day). Tumor burdens are evaluated by measuring body weights and ascites <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.   |

#### **CUSTOMER VALIDATION**

- Nature. 2024 Jan 31.
- Nature. 2022 Mar;603(7899):159-165.
- Cell Res. 2021 Sep;31(9):980-997.
- Adv Mater. 2022 Jul 28;e2204287.
- Nat Metab. 2022 Oct 10.

See more customer validations on www.MedChemExpress.com

#### REFERENCES

[1]. Yuwei Huang, et al. Migrasome formation is mediated by assembly of micron-scale tetraspanin macrodomains. Nat Cell Biol. 2019 Aug;21(8):991-1002.

[2]. Gotoh K, et al. The antitumor effects of methyl-β-cyclodextrin against primary effusion lymphoma via the depletion of cholesterol from lipid rafts. Biochem Biophys Res Commun. 2014 Dec 12;455(3-4):285-9.

[3]. Tiwari G, et al. Cyclodextrins in delivery systems: Applications. J Pharm Bioallied Sci. 2010 Apr;2(2):72-9.

[4]. Mundhara N, et al. Methyl-β-cyclodextrin, an actin depolymerizer augments the antiproliferative potential of microtubule-targeting agents. Sci Rep. 2019 May 21;9(1):7638.

[5]. Chen X, et al. Cholesterol depletion from the plasma membrane triggers ligand-independent activation of the epidermal growth factor receptor. J Biol Chem. 2002 Dec 20;277(51):49631-7.

[6]. Rodal SK, et al. Extraction of cholesterol with methyl-beta-cyclodextrin perturbs formation of clathrin-coated endocytic vesicles. Mol Biol Cell. 1999;10(4):961-974.

### Caution: Product has not been fully validated for medical applications. For research use only.

 Tel: 609-228-6898
 Fax: 609-228-5909
 E-mail: tech@MedChemExpress.com

 Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA